Abstract
For diabetes treatment, the newest kid on the block is canagliflozin (Invokana), which lowers blood glucose levels by decreasing renal tubular reabsorption of glucose and increasing urinary glucose excretion. In this double-blind, industry-sponsored trial, researchers randomized 756 patients with longstanding type 2 diabetes — all of whom …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have